On September 4, 2026, The Fertility Partners — Canada's largest network of fertility clinics — announced it had completed the sale of Illume Fertility, its US practice serving Connecticut and New York, to IVI RMA North America. The transaction closed September 3; terms were not disclosed. Illume's five offices join IVI RMA's network, which spans more than 200 locations across 15 countries with over 5,000 employees.

Why It Matters

Fertility services are where femtech's software layer eventually has to land — the apps, wearables, hormone tests and AI care plans all funnel toward a clinic, and the clinics are consolidating fast. IVI RMA at 200+ locations and 15 countries is a scale buyer, and every acquisition narrows the number of counterparties that femtech vendors need to sell into. That cuts both ways for startups: fewer, larger customers means longer sales cycles and harder procurement, but a single integration can reach far more patients than a decade of clinic-by-clinic business development. The timing sits inside a rough month for the fertility sector's independent operators. Between August 31 and September 3, Femtech Insider reported that Portugal's AI-assisted fertility clinic Ovom filed for bankruptcy and shut down without notifying patients, clinicians or health authorities, and that Italian pelvic pain telehealth startup Hale wound down in an orderly fashion. Against that backdrop, a clean asset sale into a global strategic is the healthy version of the same consolidation pressure — TFP got to choose its exit, and Illume's patients got continuity of care rather than a locked door. For the wider women's health investment picture, this is another data point that liquidity in the category is coming from strategic buyers rather than public markets. SVB data showed US women's health venture funding falling from $3.2 billion in 2024 to roughly $2 billion in 2025, and the exits materializing in 2026 have overwhelmingly been trade sales, private-equity investments and asset transfers. Oura's S-1 is the exception that proves the rule — and it isn't a fertility company.

TFP framed it as portfolio discipline rather than distress. "Illume has built a strong reputation for clinical excellence and genuine compassion for patients," said CEO Heather Stark. "We are proud of what the Illume team has accomplished and confident that IVI RMA is the right home for their next chapter. For TFP, this is about focus. Our strongest opportunities are here in Canada, and this transaction allows us to put our full attention on building the leading fertility network in the country." Stark added that TFP will "continue investing in the capabilities, infrastructure, and technology that strengthen access, improve clinical outcomes, and support the long-term evolution of fertility care in Canada."

The two-country structure had been TFP's since it expanded south, and unwinding it concentrates capital and leadership attention on a single regulatory environment — no small consideration in a sector where reimbursement, licensing and cross-border patient flows differ sharply between the US and Canada. On the buy side, IVI RMA continues a consolidation run that has made it the largest reproductive medicine group globally, adding a Northeast US footprint in two states with strong fertility-benefit coverage.

Sources

Update — 2026-09-08

{Initial entry — story first created.}

Update — 2026-10-19

Six weeks after Illume, two more moves: a new name and a donor bank. On October 14, 2026, IVI RMA North America rebranded its US operations as Everleap Fertility, bringing nine US brands, including RMA, Boston IVF and Conceptions, under one name. Femtech Insider reports the network has more than 200 physicians and embryologists across 85 clinics and IVF labs. Alongside the rebrand it launched AiVA, an AI model built on its Artemis medical-records and clinical-workflow platform and pitched as an "intelligence layer" for physicians. "We've built something remarkable across nine brands in the United States," said Everleap CEO Lynn Mason, calling it the right time "to unite under one name."

The next day, October 15, parent company IVI Institute announced that The World Egg and Sperm Bank (TWESB), a Scottsdale, Arizona-based donor egg and sperm provider serving US and Australian clinics, had "joined its global group." The release calls it an acquisition; terms were not disclosed. "There is now a growing global demand for donor eggs and donor sperm due to women delaying their first pregnancy," said IVI Institute CEO Javier Sanchez-Prieto, citing the company's own Fertility Barometer finding that 34% of US women had their first child later than expected. TWESB founder Diana Thomas said the bank will keep its existing clinic relationships while joining IVI's network.

What changed: the consolidation we described in September has moved into branding and the supply chain. One national consumer brand makes it easier to market directly to patients and to negotiate with employers. Owning a donor bank brings a scarce input (donor gametes) inside the group. And building AI into its own records platform sets Everleap up to compete with outside fertility-software vendors rather than buy from them. For femtech startups selling to clinics, that is the downside of scale: the biggest buyer is now building its own tools. For the independent donor banks still left, it is a clear signal about where they may end up.

New Sources